Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates

Vertex Pharmaceuticals Incorporated (VRTX) reported fourth-quarter 2023 adjusted earnings per share of $4.20, which beat the Zacks Consensus Estimate of$4.10. Earnings increased 12% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.Revenues of $2.52 billion surpassed the Zacks Consensus Estimate of$2.49 billion. Revenues solely comprised CF product revenues. Total product revenues rose 9.3% year over year, primarily driven by higher sales of Trik ...